Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease

Hanna Jean Khoury, Amelia A. Langston, Vamsi Kota, Jennifer A. Wilkinson, Iskra Pusic, Anand Jillella, Stephanie Bauer, Audrey S. Kim, Danielle Roberts, Zaid Al-Kadhimi, Imre Bodo, Elliott Winton, Martha Arellano, John F. Dipersio

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

Original languageEnglish (US)
Pages (from-to)826-831
Number of pages6
JournalBone marrow transplantation
Volume53
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Graft vs Host Disease
Steroids
Janus Kinases
Allografts
Lung
Skin
INCB018424
Liver

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Ruxolitinib : A steroid sparing agent in chronic graft-versus-host disease. / Khoury, Hanna Jean; Langston, Amelia A.; Kota, Vamsi; Wilkinson, Jennifer A.; Pusic, Iskra; Jillella, Anand; Bauer, Stephanie; Kim, Audrey S.; Roberts, Danielle; Al-Kadhimi, Zaid; Bodo, Imre; Winton, Elliott; Arellano, Martha; Dipersio, John F.

In: Bone marrow transplantation, Vol. 53, No. 7, 01.07.2018, p. 826-831.

Research output: Contribution to journalArticle

Khoury, HJ, Langston, AA, Kota, V, Wilkinson, JA, Pusic, I, Jillella, A, Bauer, S, Kim, AS, Roberts, D, Al-Kadhimi, Z, Bodo, I, Winton, E, Arellano, M & Dipersio, JF 2018, 'Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease', Bone marrow transplantation, vol. 53, no. 7, pp. 826-831. https://doi.org/10.1038/s41409-017-0081-5
Khoury, Hanna Jean ; Langston, Amelia A. ; Kota, Vamsi ; Wilkinson, Jennifer A. ; Pusic, Iskra ; Jillella, Anand ; Bauer, Stephanie ; Kim, Audrey S. ; Roberts, Danielle ; Al-Kadhimi, Zaid ; Bodo, Imre ; Winton, Elliott ; Arellano, Martha ; Dipersio, John F. / Ruxolitinib : A steroid sparing agent in chronic graft-versus-host disease. In: Bone marrow transplantation. 2018 ; Vol. 53, No. 7. pp. 826-831.
@article{909ae5bfcc704612821bba4e67e38315,
title = "Ruxolitinib: A steroid sparing agent in chronic graft-versus-host disease",
abstract = "Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7{\%}), cutaneous (82/0{\%}), hepatic (71/28{\%}), gastro-intestinal (75/17{\%}), musculoskeletal (33/67{\%}), pulmonary (0/80{\%}), scleroderma (0/75{\%}), vaginal (0/75{\%}), and ocular (0/100{\%}) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68{\%}) or reduction of steroids to physiologic doses (21{\%}). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.",
author = "Khoury, {Hanna Jean} and Langston, {Amelia A.} and Vamsi Kota and Wilkinson, {Jennifer A.} and Iskra Pusic and Anand Jillella and Stephanie Bauer and Kim, {Audrey S.} and Danielle Roberts and Zaid Al-Kadhimi and Imre Bodo and Elliott Winton and Martha Arellano and Dipersio, {John F.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1038/s41409-017-0081-5",
language = "English (US)",
volume = "53",
pages = "826--831",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Ruxolitinib

T2 - A steroid sparing agent in chronic graft-versus-host disease

AU - Khoury, Hanna Jean

AU - Langston, Amelia A.

AU - Kota, Vamsi

AU - Wilkinson, Jennifer A.

AU - Pusic, Iskra

AU - Jillella, Anand

AU - Bauer, Stephanie

AU - Kim, Audrey S.

AU - Roberts, Danielle

AU - Al-Kadhimi, Zaid

AU - Bodo, Imre

AU - Winton, Elliott

AU - Arellano, Martha

AU - Dipersio, John F.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

AB - Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

UR - http://www.scopus.com/inward/record.url?scp=85040911317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040911317&partnerID=8YFLogxK

U2 - 10.1038/s41409-017-0081-5

DO - 10.1038/s41409-017-0081-5

M3 - Article

C2 - 29367708

AN - SCOPUS:85040911317

VL - 53

SP - 826

EP - 831

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -